AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27116196 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) + usual care
Number of subjects: 20
Study 27116196 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 20
Study 24766625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatiguing session with five sets of bilateral dynamic knee extensions to exhaustion using a load equal to the dominant limb MVC (1-min rest between sets)
Number of subjects: 18
Study 24766625 — intervention group
Group type: COMPARATOR
Intervention: Control session (subjects sat)
Number of subjects: 18
Study 23084163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention athletes
Number of subjects: 2006
Study 23084163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention athletes (full-intensity implementation)
Number of subjects: 2006
Study 23084163 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 2006
Study 19713950 — intervention group
Group type: COMPARATOR
Intervention: Metformin XR therapy (placebo-controlled trial)
Number of subjects: 92
Study 19713950 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometry and DXA measures
Number of subjects: 92
Study 19713950 — intervention group
Group type: EXPERIMENTAL
Intervention: CT measures
Number of subjects: 92
Study 19713950 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model including waist circumference (WC) and BMI
Number of subjects: 92
Study 19713950 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression model including TG:HDL ratio and IGFBP-1
Number of subjects: 92
Study 18652113 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Simiao Tang (MST)
Number of subjects: 120
Study 18652113 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol tablet
Number of subjects: 120
Study 15975300 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuesaitong soft capsule (XST)
Number of subjects: 64
Study 15975300 — intervention group
Group type: COMPARATOR
Intervention: Dahuang Zhechong pill (NFDA1)
Number of subjects: 64
Study 14769157 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for health personnel including social, cultural, and economic aspects of tuberculosis, diagnosis and treatment, and establishment of self-help groups. Patients received a short-term treatment regimen with isoniazid, rifampin, pyrazinamide, and ethambutol for 25 weeks (105 doses).
Number of subjects: 87
Study 14769157 — intervention group
Group type: COMPARATOR
Intervention: Control group received standard treatment without the educational intervention.
Number of subjects: 87
Study 11760294 — intervention group
Group type: EXPERIMENTAL
Intervention: CON retention program intervention sessions with the Retention Coordinator
Number of subjects: 320
Study 11760294 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 320
Study 8866595 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (24 microg)
Number of subjects: 30
Study 8866595 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg)
Number of subjects: 30
Study 8866595 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 microg)
Number of subjects: 30
Study 1406078 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha‐2b interferon treatment 3 MU three times weekly for 36 weeks
Number of subjects: 33
Study 1406078 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 33
Study 3902912 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 23
Study 3902912 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 23
Study 3902912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31892680 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic Chewing Gum (ACG)
Number of subjects: 60
Study 31892680 — intervention group
Group type: COMPARATOR
Intervention: Chewing Gum (CG) without anesthetics
Number of subjects: 60
Study 31892680 — intervention group
Group type: COMPARATOR
Intervention: Control (no CG)
Number of subjects: 60
Study 30348739 — intervention group
Group type: COMPARATOR
Intervention: Control (general immunization information)
Number of subjects: 3420
Study 30348739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain pamphlet (pain mitigation information)
Number of subjects: 3420
Study 30348739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain pamphlet and pain video (pain mitigation information)
Number of subjects: 3420
Study 27846344 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg monthly for 76 weeks)
Number of subjects: 968
Study 27846344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 968
Study 22840762 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) treatment to the left temporoparietal cortex for 10 days
Number of subjects: 30
Study 22840762 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 30
Study 20820916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg twice daily
Number of subjects: 254
Study 20820916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 18549466 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel (TG)
Number of subjects: 12
Study 18549466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone gel (DHTG)
Number of subjects: 12
Study 18549466 — intervention group
Group type: COMPARATOR
Intervention: No replacement (NoRx)
Number of subjects: 12
Study 17299466 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily low-dose vitamin A (5000 IU per day)
Number of subjects: 1214
Study 17299466 — intervention group
Group type: COMPARATOR
Intervention: Single high-dose vitamin A (200,000 IU)
Number of subjects: 1214
Study 15144910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 921
Study 15144910 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 921
Study 15144910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 921
Study 11292011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (0.5 mg DMT/kg body weight)
Number of subjects: 6
Study 11292011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (0.75 mg DMT/kg body weight)
Number of subjects: 6
Study 11292011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (1.0 mg DMT/kg body weight)
Number of subjects: 6
Study 11292011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (all doses)
Number of subjects: 6
Study 11292011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (medium dose)
Number of subjects: 6
Study 9331003 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8, 12, or 16 mg)
Number of subjects: 0
Study 9331003 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0
Study 9331003 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil with HCTZ
Number of subjects: 0
Study 7898993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent exercise and relaxation
Number of subjects: 10
Study 7898993 — intervention group
Group type: COMPARATOR
Intervention: Continuous exercise
Number of subjects: 10
Study 3221745 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-propafenone 250 mg
Number of subjects: 7
Study 3221745 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-propafenone 250 mg
Number of subjects: 7
Study 3221745 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-propafenone in poor hydroxylator
Number of subjects: 7
Study 3221745 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-propafenone in poor hydroxylator
Number of subjects: 7
Study 3221745 — intervention group
Group type: EXPERIMENTAL
Intervention: Both enantiomers
Number of subjects: 7
Study 3221745 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-propafenone in efficient hydroxylators
Number of subjects: 7
Study 3221745 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-propafenone in efficient hydroxylators
Number of subjects: 7
Study 30001760 — intervention group
Group type: EXPERIMENTAL
Intervention: Step 15 exposure therapy (allowing a spider to walk freely over one's body)
Number of subjects: 51
Study 30001760 — intervention group
Group type: COMPARATOR
Intervention: Step 14 or fewer exposure therapy steps
Number of subjects: 51
Study 26599991 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG biofeedback (neurofeedback) training to increase left anterior theta power (NF‐HYP)
Number of subjects: 20
Study 26599991 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control condition (RLX‐HYP)
Number of subjects: 20
Study 25720854 — intervention group
Group type: EXPERIMENTAL
Intervention: ASR implants
Number of subjects: 46
Study 25720854 — intervention group
Group type: COMPARATOR
Intervention: ReCap implants
Number of subjects: 46
Study 22642937 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone
Number of subjects: 89
Study 22642937 — intervention group
Group type: EXPERIMENTAL
Intervention: raloxifene
Number of subjects: 89
Study 22642937 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 89
Study 22147343 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese preparation of rhGH (GenHeal®, 1.6 mg (4 IU), Shanghai, China) administered at a dose of 0.1 IU/kg body weight, one injection per day for 14 days.
Number of subjects: 25
Study 22147343 — intervention group
Group type: EXPERIMENTAL
Intervention: Swiss preparation of rhGH (Saizen®, 1.33 mg (4 IU), Laboratoires Serone S.A., Switzerland) administered at a dose of 0.1 IU/kg body weight, one injection per day for 14 days.
Number of subjects: 25
Study 22147343 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (6 volunteers).
Number of subjects: 25
Study 18972290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate (BDP; 400 microg/d)
Number of subjects: 33
Study 18972290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 19952770 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional walking
Number of subjects: 60
Study 19952770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometry training
Number of subjects: 60
Study 19952770 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation program
Number of subjects: 60
Study 15614573 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg dexamphetamine
Number of subjects: 20
Study 15614573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12168743 — intervention group
Group type: EXPERIMENTAL
Intervention: One-arm hop test for football players
Number of subjects: 26
Study 12168743 — intervention group
Group type: EXPERIMENTAL
Intervention: One-arm hop test for wrestlers
Number of subjects: 26
Study 9537786 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin nasal challenge
Number of subjects: 3
Study 9537786 — intervention group
Group type: COMPARATOR
Intervention: Vehicle nasal challenge
Number of subjects: 3
Study 8032830 — intervention group
Group type: EXPERIMENTAL
Intervention: Evans BCG
Number of subjects: 99
Study 8032830 — intervention group
Group type: COMPARATOR
Intervention: Pasteur BCG
Number of subjects: 99
Study 2645120 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 235
Study 2645120 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 235
Study 11968802 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway group (32 patients)
Number of subjects: 69
Study 11968802 — intervention group
Group type: COMPARATOR
Intervention: Non-pathway group (37 patients)
Number of subjects: 69
Study 11968802 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 69
Study 29858133 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural block (CEB) plus general anesthesia (GA)
Number of subjects: 57
Study 29858133 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA) only
Number of subjects: 57
Study 27542357 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Moms intervention (6-month smartphone-delivered program)
Number of subjects: 0
Study 27542357 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study 23983274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP)
Number of subjects: 553
Study 23983274 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS)
Number of subjects: 553
Study 23983274 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TIP and TIS
Number of subjects: 553
Study 22030902 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative liver function tests (QLFTs)
Number of subjects: 227
Study 22030902 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose elimination capacity (GEC)
Number of subjects: 227
Study 22030902 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual cholate (CA) clearance after oral administration (Cl(oral))
Number of subjects: 227
Study 22030902 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine elimination rate (k(elim)), antipyrine (AP) clearance (Cl), MEGX concentration, methionine breath test (MBT), galactose elimination capacity (GEC), dual cholate (CA) clearances and shunt, perfused hepatic mass (PHM), and liver and spleen volumes
Number of subjects: 227
Study 22030902 — intervention group
Group type: EXPERIMENTAL
Intervention: CA Cl(oral) or PHM
Number of subjects: 227
Study 22030902 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk QLFTs
Number of subjects: 227
Study 20585735 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor cycling (CI)
Number of subjects: 40
Study 20585735 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor cycling combined with low-calorie diet (CD)
Number of subjects: 40
Study 20585735 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (D)
Number of subjects: 40
Study 20585735 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 40
Study 17916068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic irrigation
Number of subjects: 40
Study 17916068 — intervention group
Group type: COMPARATOR
Intervention: Static irrigation
Number of subjects: 40
Study 15983093 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% dextrose (5 g in 50 ml)
Number of subjects: 51
Study 15983093 — intervention group
Group type: COMPARATOR
Intervention: 50% dextrose (5 g in 10 ml)
Number of subjects: 51
Study 12915671 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg twice daily)
Number of subjects: 20
Study 12915671 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 10700785 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 60
Study 10700785 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 60
Study 10700785 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 60
Study 10700785 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine
Number of subjects: 60
Study 8520499 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative therapy supported by autologous bone marrow or blood stem cell transplantation
Number of subjects: 41
Study 1836486 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule with recombinant hepatitis B vaccine (Engerix-B)
Number of subjects: 132
Study 1836486 — intervention group
Group type: COMPARATOR
Intervention: Conventional vaccination regimen
Number of subjects: 132
Study 1836486 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule
Number of subjects: 132
Study 6769666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (500 mg) in fasting (A)
Number of subjects: 6
Study 6769666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (500 mg) with a meal (B)
Number of subjects: 6
Study 6769666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (500 mg) 3 hours after a meal (C)
Number of subjects: 6
Study 6769666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus dose of VPA (400 mg) 3 hours after a meal
Number of subjects: 6
Study 30895706 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES) in diabetics
Number of subjects: 1497
Study 30895706 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) in diabetics
Number of subjects: 1497
Study 30895706 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES) in nondiabetics
Number of subjects: 1497
Study 30895706 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) in nondiabetics
Number of subjects: 1497
Study 30895706 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes in diabetics
Number of subjects: 1497
Study 29742263 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC + 4.5% DOX
Number of subjects: 0
Study 29742263 — intervention group
Group type: COMPARATOR
Intervention: RMGIC (control)
Number of subjects: 0
Study 29742263 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC + 1.5% DOX
Number of subjects: 0
Study 29742263 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGIC + 3% DOX
Number of subjects: 0
Study 27574418 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program (group education session, individual training on inhalation techniques, written action plan)
Number of subjects: 0
Study 27574418 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 0
Study 25243929 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health volunteers
Number of subjects: 5643
Study 25243929 — intervention group
Group type: COMPARATOR
Intervention: Care seeking from an appropriate provider
Number of subjects: 5643
Study 22861171 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of tool before regularly scheduled visit
Number of subjects: 135
Study 22861171 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study 21186964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 131
Study 21186964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 21186964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 131
Study 17295569 — intervention group
Group type: EXPERIMENTAL
Intervention: Schema-focused therapy (SFT)
Number of subjects: 78
Study 17295569 — intervention group
Group type: COMPARATOR
Intervention: Transference-focused psychotherapy (TFP)
Number of subjects: 78
Study 17295569 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment negative ratings
Number of subjects: 78
Study 17295569 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive ratings in the 1st half of treatment
Number of subjects: 78
Study 17295569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissimilarity in pathological personality characteristics
Number of subjects: 78
Study 16232343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of Bacillus Calmette‐Guérin polysaccharide nucleotide (BCG‐PSN)
Number of subjects: 120
Study 16232343 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of BCG‐PSN
Number of subjects: 120
Study 16232343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of BCG‐PSN (36 times)
Number of subjects: 120
Study 16232343 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 120
Study 12199724 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 291
Study 12199724 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 291
Study 11793634 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib as adjunctive therapy
Number of subjects: 0
Study 11793634 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10530098 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B Ultra Plaque Remover (D9)
Number of subjects: 49
Study 10530098 — intervention group
Group type: EXPERIMENTAL
Intervention: Braun Oral‐B 3D Plaque Remover (3D)
Number of subjects: 49
Study 10530098 — intervention group
Group type: COMPARATOR
Intervention: Both toothbrushes
Number of subjects: 49
Study 7993328 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry suppression
Number of subjects: 0
Study 7993328 — intervention group
Group type: COMPARATOR
Intervention: Non-worrying thought
Number of subjects: 0
Study 7993328 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming condition
Number of subjects: 0
Study 2727071 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental physical therapy program (six one-minute activities in side-lying and supported-sitting positions)
Number of subjects: 14
Study 2727071 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental physical therapy program
Number of subjects: 14
Study 799561 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (75-300 mg)
Number of subjects: 23
Study 799561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31483155 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute antioxidant (AO) administration (600 mg α-lipoic acid, 1,000 mg vitamin C, and 600 IU vitamin E)
Number of subjects: 16
Study 31483155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 16
Study 31483155 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute antioxidant (AO) administration
Number of subjects: 16
Study 29138135 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular strategy (316 patients, 275 with confirmed rupture)
Number of subjects: 613
Study 29138135 — intervention group
Group type: COMPARATOR
Intervention: Open repair (297 patients, 261 with confirmed rupture)
Number of subjects: 613
Study 29138135 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular strategy (502 patients with repaired ruptures)
Number of subjects: 613
Study 29138135 — intervention group
Group type: COMPARATOR
Intervention: Open repair (502 patients with repaired ruptures)
Number of subjects: 613
Study 29138135 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular strategy
Number of subjects: 613
Study 29138135 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 613